Celiac disease is a genetic autoimmune disorder that affects approximately 1% of the global population. In celiac disease, ingestion of gluten leads to damage of the villi in the small intestine. This can lead to long-term health conditions such as vitamin and mineral deficiencies and early onset of osteoporosis or osteopenia. Furthermore, it can lead to more malignant conditions such as Non-Hodgkin lymphoma and small intestinal adenocarcinoma.
There is no approved drug for the treatment of Celiac disease. No medication exists that can prevent the immune attack or repair the damage to the villi resulting from exposure to gluten. Therefore, current treatment is limited to maintaining a gluten-free diet. Failure to comply with a gluten-free diet, especially when inadvertent at a restaurant or cafeteria, will typically lead to relapse as the underlying pathology of celiac disease remains unaddressed.
TIMP-GLIA seeks to prevent these long-term and severe conditions by tolerizing the body to gluten. Using Cour’s novel technology for TIMP-GLIA, the body is reprogrammed to recognize gluten as a non-threatening substance and subsequently abrogates/reverses the signs and symptoms of Celiac disease.
TIMP-GLIA is currently in clinical trials. To learn more, visit clinicaltrials.gov.
Food and Environmental allergies are Immunoglobulin E-mediated (IgE) responses to food and environmental allergens. Symptoms can range from allergic rhinitis to life-threatening anaphylaxis. Typical treatment of allergies involves avoidance of the allergen or management of the symptoms with medications such as anti-histamines. Furthermore, current immunotherapy treatments provide limited protection and/or only prevent accidental exposure to the allergen (i.e. accidentally consuming a peanut butter cookie).
Eight types of food account for about 90% of all food-related allergic reactions. These foods are: Eggs, Milk, Peanuts, Tree Nuts, Fish, Shellfish, Wheat, and Soy. Environment allergens can be plant, animal, or insect based. Common environmental allergens include pollen, cats, dogs, and dust mites. Cour is specifically developing therapeutics modeled from our TIMP platform technology to treat the wide array of food and environmental allergies.
Multiple Sclerosis (MS) is a debilitating autoimmune disease affecting an estimated 1 million people in the US. MS is characterized by the dysregulated immune response towards myelin proteins of neurons that causes the destruction of neurons, disrupts the flow of information within the central nervous system, and ultimately results in disease symptoms such as loss of movement, impaired vision, and fatigue. Existing therapies for MS rely on immune suppressant regimens that cause severe side-effects and compromise quality of life.
COUR’s CNP-201 nanoparticles is first-in-class therapy for MS designed to reprogram the immune system to rebuild tolerance to myelin proteins and provide long-term therapeutic benefit by preventing immune-mediated destruction of neurons and allowing the regeneration of damaged neurons.
Neuromyelitis Optica (NMO) is a rare autoimmune disease that stems from immune reactivity to self-antigens, primarily Aquaporin-4, found on cells in the eye and the central nervous system. NMO is characterized by symptoms such as blindness, weakness or paralysis, loss of sensation, and spinal cord damage.
Existing therapies in use in the clinic or under development for the treatment of NMO are aimed at broadly suppressing the immune system. While these therapies relieve symptoms, they do not address the underlying causes driving disease and result in severe side-effects.
COURs breakthrough nanoparticle technology is designed to address the fundamental mechanisms that drive NMO disease symptoms by reprogramming the immune system to once again tolerate the self-antigens associated with NMO. Our breakthrough technology will provide long-term therapeutic benefit without causing immune suppressive side-effects.
The immune system recognizes biologics and gene therapies as foreign and responds by producing neutralizing antibodies against them. Neutralizing antibodies swiftly bind and inhibit biologics and gene therapies which renders them therapeutically effective. Neutralizing antibodies are a major clinical challenge as repeated dosing of biologics and gene therapies, essential for continued therapeutic efficacy, becomes impossible.
So far, clinicians have relied on co-administration of immune suppressant regimens with biologics and gene therapies to overcome neutralizing antibodies; however, these immune suppressive regimens have limited usefulness and come with the high cost of severe side-effects and poor quality of life.
COUR’s breakthrough nanoparticle platform is designed to reprogram the immune system to induce immune tolerance to biologics and gene therapies – either prior to or alongside treatment. Our technology provides clinicians with a safe, effective, and non-immune suppressive approach that allows repeated dosing of biologics and gene therapies without the concern of inducing neutralizing antibodies.